The Significance of Hormone Receptors to Predict the Endocrine Responsiveness of Human Breast Cancer

References

• Lippman M E. Steroid hormone receptors and mechanisms of growth regulation of human breast cancer. Diagnosis and management of breast cancer, M E Lippman, A S Lichter, D N Danforth. WB Saunders Company. 1988; 326–47
   Google Scholar
• Stewart J F, King R JB, Sexton S A, Millis R R, Rubens R D, Hayward J L. Oestrogen receptors, Sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 1981; 17: 449–53
   Google Scholar
• Beex L VAM, Koenders A JM. Is hormonal responsiveness in breast cancer age dependent. Rev Endocrine Rel Cancer 1984; 19: 5–10
   Google Scholar
• Standford J L, Szklo M, Brinton L A. Estrogen receptors and breast cancer. Epidemiologic Rev 1986; 8: 42–59
   Google Scholar
• Howat J MT, Barnes D M, Harris M, Swindell R. The Association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer 1983; 47: 629–40
   PubMed Web of Science ®Google Scholar
• Masters J RW, Millis R R, Rubens R D. Response to endocrine therapy and breast cancer differentiation. Breast Cancer Res Treat 1986; 7: 31–4
   Google Scholar
• Baildam A D, Howell A, Barnes D M, et al. Expression of differentiation antigens within human mammary tumours is related to response to endocrine therapy and survival. Int J Cancer 1988; 42: 154–8
   Google Scholar
• Howell A, Wakeling A E. Steroid and peptide hormones and growth factors. Cancer chemotherapy and biological response modifiers annual 10, H M Pinedo, D L Longo, B A Chabner. Elsevier Sci Publ. 1988; 117–332
   Google Scholar
• Bronzert D A, Davidson M, Lippman M. Estrogen and antiestrogen resistance in human breast cancer cell lines. Adv Exp Med Biol 1986; 196: 329–45
   PubMedGoogle Scholar
• Paterson A HG, Cyr M, Szafran O, Lees A W, Hanson J. Response to treatment and its influence on survival in metastatic breast cancer. AM J Clin Oncol 1985; 8: 283–92
   PubMed Web of Science ®Google Scholar
• Jensen E V, Block G E, Smith S, Kyser K, de Sombre E R. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971; 34: 55–79
   PubMedGoogle Scholar
• Wittliff J L. Steroid-hormone receptors in breast cancer. Cancer 1984; 53: 630–43
   PubMed Web of Science ®Google Scholar
• Siebert I T, Lippman M E. Hormone receptors in breast cancer. Clin Oncol 1982; 1: 735–94
   Google Scholar
• Scholl S, Lippman M E. Methods and clinical use of receptor assay. Breast cancer: Diagnosis and management, G Bonadonna. John Wiley & Sons. 1984; 75–108
   Google Scholar
• Lippman M E, Allegra J C. Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 1980; 46: 2829–34
   PubMed Web of Science ®Google Scholar
• Paridaens R, Sylvester R J, Ferrazzi E, Legros N, Leclercq G, Heuson J C. Clinical significane of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 1980; 46: 2889–95
   PubMed Web of Science ®Google Scholar
• Fernö M, Borg Å, Selberg G. Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 1986; 25: 171–5
   PubMed Web of Science ®Google Scholar
• Jordan V C, Jacobson H I, Keenan E J. Determination of estrogen receptor in breast cancer using monoclonal antibody technology: Results of a multicenter study in the United States. Cancer Res 1986; 46(Suppl)4237–40
   Google Scholar
• Leclercq G, Bojar H, Goussard J, et al. Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: A European multicenter study. Cancer Res 1986; 46(Suppl)4233–6
   PubMedGoogle Scholar
• Pousette Å, Gustafsson S A, Thörnblad A M, et al. Quantitation of estrogen receptor in seventy-five specimens of breast cancer: Comparison between an immunoassay (Abbott ER-EIA monoclonal) and a (3H) estradiol binding assay based on isoelectric focusing in polyacrylamide gel. Cancer Res 1986; 46(Suppl)4308–9
   Google Scholar
• Pertschuk L P, Eisenberg K B, Carter A C, Feldman J G. Heterogeneity of estrogen binding sites in breast cancer: Morphologic demonstration and relationship to endocrine response. Breast Cancer Res Treat 1985; 5: 137–47
   PubMedGoogle Scholar
• Hawkins R A, Sangster K, Tesdale A, et al. The cytochemical detection of estrogen receptors in fine needle aspirates of breast cancer; Correlation with biochemical assay and prediction of response to endocrine theapy. Br J Cancer 1988; 58: 77–80
   PubMed Web of Science ®Google Scholar
• McClelland R A, Berger U, Miller L S, Powles T J, Jensen E V, Coombes R C. Immunocytochemical assay for estrogen receptor: Relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res 1986; 46(Suppl)4241–3
   PubMedGoogle Scholar
• Jonat W, Maas H, Stegner H E. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res 1986; 46(Suppl)4296–8
   PubMedGoogle Scholar
• Gaskell D J, Hawkins R A, Sangsterl K, Chetty U, Forrest A PM. Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet 1989; 1: 1044–6
   PubMed Web of Science ®Google Scholar
• Coombes R C. Endocrine treatment of breast cancer: Current concepts and future approaches. The new endocrinology of cancer, J Waxman, R C Coombes. Edward Arnold (Publ) Ltd. 1987; 54–77
   Google Scholar
• McGuire W L, Clark G M. Progesterone receptors and human breast cancer; ‘Wassink Lecture’ presented at the 3rd EORTC Breast Cancer Working Conference. Eur J Cancer 1983; 19: 1681–5
   Google Scholar
• Sedlacek S M, Hoewitz K B. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids 1985; 44: 467–84
   Google Scholar
• Raemaekers J M, Beex L V, Pieters G F, Smals A G, Benraad T J, Kloppenborg P W, The Breast Cancer Study Group. Progesterone receptor acitivity and the response to the first endocrine therapy in advanced breast cancer. Eur J Cancer 1987; 23: 443–8
   Google Scholar
• Gross G E, Clark G M, Chamness G C, McGuire W L. Multiple progesterone receptor assays in human breast cancer. Cancer Res 1984; 44: 836–40
   PubMed Web of Science ®Google Scholar
• Harland R NL, Barnes D M, Howell A, Ribeiro G G, Taylor J, Sellwood R A. Variation of receptor status in cancer of the breast. Br J Cancer 1983; 47: 511–5
   PubMedGoogle Scholar
• Osborne C K. Heterogenity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 1985; 12: 317–26
   PubMed Web of Science ®Google Scholar
• Reiner G CA, Katzenellenbogen B S. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells. Cancer Res 1986; 46: 1124–31
   Google Scholar
• Sainsbury J RC, Farndon J R, Harris A L, Sherbet G V. Epidermal growth factor receptors on human breast cancers. Br J Surg 1985; 72: 186–8
   PubMed Web of Science ®Google Scholar
• Macias A, Azavedo E, Hägerström T, Klintenberg C, Pérez R, Skoog L. Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. Anticancer Res 1987; 7: 459–64
   PubMed Web of Science ®Google Scholar
• Nicholson S, Sainsbury J RC, Halcrow P, Chambers P, Farndon J R, Harris A L. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989; 1: 182–5
   PubMed Web of Science ®Google Scholar
• Sutherland R L, Murphy L C. The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer 1980; 16: 1141–8
   PubMed Web of Science ®Google Scholar
• Wakeling A E. Cellular mechanisms in tamoxifen action on tumours. Rev Endocrine-Rel Cancer 1988; 30: 27–33
   Google Scholar
• Miller W R, Telford J, Dixon J M, Hawkins R A. Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer 1985; 21: 539–42
   Google Scholar
• Bryan R M, Mercer R J, Bennett R C, Rennie G C, Lie T H, Morgan F J. Androgen receptors in breast cancer. Cancer 1984; 54: 2436–440
   PubMed Web of Science ®Google Scholar
• Adjuvant Trial Organisation. Analysis at eight years by ‘nolvadex’. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988; 57: 608–11
   Google Scholar
• Report from the Breast Cancer Trials Committee. Scottish Cancer Trials office (MRC), Edinburgh. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1987; 2: 171–5
   Google Scholar
• Rutqvist L E, Cedermark B, Glas U, et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 1987; 10: 255–66
   PubMed Web of Science ®Google Scholar
• Rose C, Thorpe S M, Andersen K W, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985; 1: 16–19
   PubMed Web of Science ®Google Scholar
• Rutqvist L E, Cedermark B, Fornander T, et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989; 7: 1474–84
   PubMed Web of Science ®Google Scholar
• McCarty K S, Szabo E, Flowers J L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46(Suppl)4244–8
   Google Scholar